A mental health checkup for children and adolescents, a year into COVID As a whole, this group experienced a significant short-term psychological toll. Though the long-term consequences aren’t yet known, particularly given how the year disproportionately exacerbated adverse childhood experiences, Penn experts remain cautiously optimistic.
A school year like no other is about to end. The weather is warming up. In many places across the United States, COVID case numbers have been dropping and continue to decrease, meaning camps and other summer outdoor activities can likely proceed.
Yet it’s been a long road, one that’s taken a significant psychological toll on children and adolescents in the short term. Emergency Departments (ED) are reporting more visits for mental health struggles, with admitted patients staying longer. Incidence of anxiety and depression have increased, exacerbated by the social isolation and loneliness induced by the requireme
The study found that levels of economic prosperity across the U.S. directly correlated to death rates from heart disease and stroke in middle-aged Americans.
The initiative, called the Action for Cultural Transformation, was announced at the 7th Annual Martin Luther King, Jr. Health Equity Symposium on Feb. 3.
What drives people away from medication for opioid use disorder?
The opioid epidemic is in its fourth and possibly deadliest wave, exacerbated by the COVID-19 pandemic and disproportionately killing people of color. Medications for opioid use disorder (MOUD) including methadone, buprenorphine, and naltrexone are effective in combatting the epidemic, but sorely underused. Philadelphia’s Department of Behavioral Health and Intellectual disability Services recently enacted a suite of policies to remove logistical, structural, and payment barriers to MOUD in the publicly-funded behavioral health system, but some facilities still do not use these medications.
To better understand MOUD barriers, Penn Leonard Davis Institute of Health Economics experts interviewed 25 executive directors of publicly funded treatment organizations in Philadelphia that adopted or did not adopt MOUD, finding that stigma towards medications and ideological beliefs about MOUD treatment contribute to non-adop